Total receipts for the three months ended Sept. 30 increased to 256.3 million from $197 million one year ago. Invitrogen said BioDiscovery grew 17 percent year over year, while BioProduction surged 53 percent.
R&D spending also increased in the third quarter, to $19.2 million from $15.4 million year over year.
Net income jumped to $28.7 million, or $.54 per basic share, from $13.7 million, or $.27 per basic share, one year ago.
Invitrogen said it had around $939.8 million in cash and investments as of Sept. 30.
The company reiterated its 2004 revenue forecast of around $1 billion.
As GenomeWeb News reported yesterday, Invitrogen acquired DNA Research Innovations of Kent,
Privately held DNA Research Innovation develops and sells ChargeSwitch technology, a DNA/RNA purification technology.
The acquisition follows Invitrogen's purchase of Protometrix in April; Xeotron in May; and Molecular Probes in August.